PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading
developer of targeted, systemic RNA interference (RNAi) therapeutics, today
announced the issuance of United States patent 7,459,547, entitled "Methods
and Compositions for Controlling Efficacy of RNA Silencing." The issued
patent, which is based on the seminal research of Philip Zamore, Ph.D., the
Gretchen Stone Cook Chair of Biomedical Sciences and Professor of Biochemistry
& Molecular Pharmacology at
"There is little dispute among those involved in the RNAi sector that proper siRNA structure and design is taking on an increasingly important role in the development of next generation RNAi therapeutics," said James Topper, M.D., Ph.D., general partner at Frazier Healthcare Ventures and chairman of Intradigm's board of directors. "Accordingly, the siRNA structure claims of this issued patent provide Intradigm with another important tool in the company's efforts to realize the tremendous therapeutic promise of RNA interference."
"Ongoing scientific research has highlighted the importance of siRNA structure as a critical component of an effective RNAi therapeutic and the issuance of this patent provides Intradigm with a significant competitive advantage in this area," said Mike Riley, Intradigm's vice president of intellectual property and corporate development. "For Intradigm, this patent becomes even more valuable when combined with the company's proprietary RNAi sequences and delivery technologies. Ultimately, access to this intellectual property will allow Intradigm to create a high value pipeline of well- protected products developed by incorporating novel, enhanced RNAi sequences into the company's innovative RNAi delivery systems."
Intradigm possesses one of the industry's strongest RNAi IP positions
including key assets strategically licensed from both the
Intradigm is a private biotechnology company committed to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. Intradigm is unique, among private companies, with its comprehensive RNAi therapeutics platform consisting of structural features for next- generation of RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics and proprietary siRNA sequence applications. Our proprietary delivery technology is unique in its potential to offer safe and effective systemic administration using a library of novel peptide-based biodegradable polymers.
We have established an impressive proprietary portfolio of siRNA sequences
against more than 50 highly valued oncology and other disease targets. In
addition, we have secured an exclusive license to the Zamore patent family
For more information on Intradigm, please visit http://www.intradigm.com.
|SOURCE Intradigm Corporation|
Copyright©2008 PR Newswire.
All rights reserved